Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2025

Safety profile of upadacitinib: Descriptive analysis in over 27,000 patient‑years across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and inflammatory bowel disease

Adv Ther 2025 Doi: 10.1007/s12325-025-03328-y Epub ahead of print

Levy G,

Palac H,

Ford S,

This descriptive analysis indicates a long-term safety profile of UPA consistent with previous reports, further supporting long-term treatment of chronic diseases with UPA. Burmester at al. characterized the safety profile of UPA across multiple approved indications and offer insights into its long-term use to help inform clinical decision-making.

Keywords:

August 2025

A real-world comparison of clinical effectiveness of upadacitinib, tumor necrosis factor inhibitors or interleukin-17 inhibitors in patients with axial spondyloarthritis after switching from an initial tumor necrosis factor inhibitor treatment

Rheumatol Ther 2025; Epub ahead of print doi: 10.1007/s40744-025-00786-2

Ye X,

Baraliakos et al. compared real-world effectiveness of upadacitinib, TNF inhibitors, or IL-17 inhibitors following inadequate response to an initial TNF inhibitor in patients with axSpA. Upadacitinib was associated with greater reductions in pain and fewer affected joints compared with switching to a second TNF inhibitor or IL-17 inhibitor.

Keywords:

July 2025

Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: A post hoc analysis from placebo-controlled Phase 3 studies with secukinumab

Ther Adv Musculoskelet Dis. 2025;17:1–7

Quebe-Fehling E and Deodhar A

Brandt-Jürgens et al. identified a difference between the incidence rates of uveitis in patients with PsA or axSpA when treated with secukinumab compared to placebo. The authors conducted a post hoc analysis of 11 placebo-controlled clinical trials which has observed that uveitis incidences in patients with PsA are consistent with clinical trial data, and patients with axSpA show a lower incidence of uveitis compared to other publications.

Keywords:

Ixekizumab and malignant neoplasms A pooled analysis of data from 25 randomized clinical trials

Merola et al. JAMA Dermatol 2025; 9:e252056

Papp KA,

Zhu D,

Inman E,

Grace E,

Merola et al. showed that the safety profile of ixekizumab (IXE) supports its long-term use in patients with PsO, PsA, or axSpA, without an increased risk for malignant neoplasm development. Merola et al. investigated the incidence rates of malignant neoplasms among patients with PsO, PsA, or axSpA who underwent long-term treatment with IXE, an IL- 17A antagonist.

Keywords:

March 2025

Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study

Arthritis Res Ther. 2025;27:23. doi: 10.1186/s13075-024-03441-3

Kim TH,

Bu X,

Song IH,

Wung P,

Kato K,

Shmagel A

Van den Bosch et al. reported that upadacitinib 15 mg once daily led to sustained improvement in nr-axSpA over two years, including disease activity, pain, and quality of life. The study reports that 57.1% achieved ASAS40 response at week 104, with no new safety signals identified.

Keywords:

February 2025

Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension

MD Open. 2025;11:e005081 doi: 10.1136/rmdopen-2024-005081

Vaux T,

Deodhar et al. assessed the long-term safety, tolerability and efficacy of bimekizumab in patients with r-axSpA over five years. The study found that bimekizumab maintained disease control achieved at Wk48 through Wk256, with no new safety signals observed. Adverse events were consistent with previous reports, and clinical benefits, including improvements in disease activity and patient-reported outcomes, were sustained.

Keywords:

Long-Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

Rheumatol. 2025. Epub ahead of print. doi: 10.1093/rheumatology/keaf009

Xu H,

Vaux T,

Baraliakos et al. evaluated the long-term safety and efficacy of bimekizumab in axSpA through a 2-year analysis of the BE MOBILE 1 and BE MOBILE 2 studies. Bimekizumab was well tolerated, with a consistent safety profile and no new safety signals. Clinical improvements, including ASAS40 response and MRI remission, were sustained through Wk104.